Conexiant’s news site is now MDSpire News. Learn more
Advertisement
ASCO26: Toni Choueiri, MD, KEYNOTE-654
Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.
Clinical Report: ctDNA Assay Limitations in KEYNOTE-564 Trial
Overview
The ctDNA assay used in the KEYNOTE-564 trial showed low sensitivity in predicting outcomes for renal cell carcinoma patients treated with adjuvant pembrolizumab. ctDNA positivity correlated with worse disease-free survival.
Background
The assessment of circulating tumor DNA (ctDNA) has emerged as a potential biomarker for predicting cancer outcomes. In the context of renal cell carcinoma (RCC), understanding the efficacy of ctDNA assays is important for patient management, particularly regarding adjuvant therapies like pembrolizumab.
Data Highlights
No numerical data available in the source material.
Key Findings
ctDNA positivity was associated with worse disease-free survival in both treatment arms of the KEYNOTE-564 trial.
Baseline ctDNA was detectable in only 5.4% (16-plex) and 8.2% (64-plex) of patients.
The ctDNA assays demonstrated high specificity but low sensitivity for recurrence risk.
Pembrolizumab showed benefit regardless of baseline ctDNA status.
On-treatment ctDNA clearance occurred more frequently with pembrolizumab compared to placebo.
Current exome-based ctDNA assays do not support routine patient selection for adjuvant pembrolizumab in high-risk RCC.
Clinical Implications
The low sensitivity and positivity rates of ctDNA assays indicate limitations in their use for guiding adjuvant treatment decisions in RCC.
Conclusion
The findings from the KEYNOTE-564 trial indicate that ctDNA may correlate with disease outcomes, but its limitations should be considered in clinical contexts.
Kidney cancer is a growing global health problem, and both clinicians and policymakers need to prepare for a steep rise in the number of cases,” said Alexander Kutikov, MD, FACS, Chair of the Department of Urology at Fox Chase Cancer Center, and senior author of a landmark international study published in European Urology, which demonstrates that if current trends continue, kidney cancer cases could double by 2050
Genetic testing may be the most effective way for researchers to distinguish between a rare form of kidney cancer and another that is more common, potentially preventing misdiagnoses, according to a recent study by researchers at Fox Chase Cancer Center and Temple University Hospital.
